Form 8-K - Current report:
SEC Accession No. 0001193125-25-056750
Filing Date
2025-03-18
Accepted
2025-03-18 17:20:45
Documents
13
Period of Report
2025-03-18
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d857499d8k.htm   iXBRL 8-K 78725
  Complete submission text file 0001193125-25-056750.txt   207693

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA itci-20250318.xsd EX-101.SCH 2896
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20250318_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20250318_pre.xml EX-101.PRE 10843
15 EXTRACTED XBRL INSTANCE DOCUMENT d857499d8k_htm.xml XML 3488
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 25749631
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)